gentamicin has been researched along with Obesity in 22 studies
Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A major and significant weight gain can occur after a six-week intravenous treatment by vancomycin plus gentamycin for IE with a risk of obesity, especially in males older than 65 who have not undergone surgery." | 7.76 | Vancomycin treatment of infective endocarditis is linked with recently acquired obesity. ( Angelakis, E; Casalta, JP; Habib, G; Raoult, D; Richet, H; Thuny, F, 2010) |
| "Gentamicin volume of distribution (V) was related to body weight (W) in 183 obese, normal weight and infant patients as reported in five published studies." | 7.67 | Gentamicin volume of distribution as a power function of body weight. ( Keller, F, 1989) |
| "The effect of obesity on gentamicin disposition was studied in 60 obstetric and gynecologic patients receiving treatment for Gram-negative infections." | 7.66 | Effect of obesity on gentamicin pharmacokinetics. ( Cipolle, RJ; Lesar, T; Sketris, I; Zaske, DE, 1981) |
| "Gentamicin was administered at 2." | 5.48 | The "Ideal" Body Weight for Pediatric Gentamicin Dosing in the Era of Obesity: A Population Pharmacokinetic Analysis. ( Galati, M; Kam, C; Moffett, BS; Palazzi, DL; Revell, PA; Schmees, L; Stitt, GA, 2018) |
| " The impact of obesity on intrinsic susceptibility to gentamicin nephrotoxicity was assessed by dosing animals for 5 days to ideal body mass plus 40% of excess body mass, the current clinical practice for achieving normal gentamicin concentrations in obese patients." | 5.28 | Obesity as a risk factor in drug-induced organ injury. IV. Increased gentamicin nephrotoxicity in the obese overfed rat. ( Corcoran, GB; Salazar, DE, 1989) |
| " We evaluated the pharmacokinetics and AKI potential of gentamicin in 14-week-old diet-induced obesity-prone (n = 40) and obesity-resistant (n = 40) rats of both sexes." | 3.79 | Effects of obesity and sex on antimicrobial pharmacokinetics and acute kidney injury: validation of a preclinical model. ( Chen, WZ; Cui, H; El-Fawal, HA; Garba, A; Mousa, SA; Pai, MP; Zaffo, B, 2013) |
| "A major and significant weight gain can occur after a six-week intravenous treatment by vancomycin plus gentamycin for IE with a risk of obesity, especially in males older than 65 who have not undergone surgery." | 3.76 | Vancomycin treatment of infective endocarditis is linked with recently acquired obesity. ( Angelakis, E; Casalta, JP; Habib, G; Raoult, D; Richet, H; Thuny, F, 2010) |
| "Gentamicin volume of distribution (V) was related to body weight (W) in 183 obese, normal weight and infant patients as reported in five published studies." | 3.67 | Gentamicin volume of distribution as a power function of body weight. ( Keller, F, 1989) |
| " In this period, several new population pharmacokinetic studies have focused on these subpopulations, providing insights into the typical values of the most relevant pharmacokinetic parameters, the variability of these parameters and possible explanations for this variability, although unexplained variability often remains high." | 2.82 | Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review. ( de Vroom, SL; Hodiamont, CJ; Mathôt, RAA; Prins, JM; van den Broek, AK; van Hest, RM, 2022) |
| "Deep-space surgical site infections carry significant morbidity and mortality." | 1.72 | Gentamicin-Containing Collagen Implant May Reduce Surgical Site Infections After Open Infrainguinal Arterial Revascularization. ( Garbowski, MW; Hockley, JA; Jacques, A; Jansen, SJ; Kwok, CHR; Stopher, L; Zhao, AH, 2022) |
| "A consistent approach to the dosing of aminoglycosides across the modern body size distribution has been elusive." | 1.48 | Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance across Body Size. ( Crass, RL; Derstine, BA; Lichty, M; Pai, MP; Ross, BE; Su, GL; Sullivan, JA; Wang, SC, 2018) |
| " Dosing of aminoglycosides is typically based on total body weight." | 1.37 | Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients. ( Bertino, JS; Nafziger, AN; Pai, MP, 2011) |
| "Gentamicin monitoring has been improved with the introduction of Bayesian methods but the usefulness depends on the quality of the population parameters (PP) used." | 1.30 | Population pharmacokinetic parameters of gentamicin in patients with solid tumors: estimation by one- and two-stage methods. ( Aldaz, A; Brugarolas, A; Giráldez, J; Ortega, A, 1998) |
| "A total of 198 cancer patients were included in the study." | 1.30 | Relationship between pharmacokinetic parameters of gentamicin and patient characteristics and/or clinical data in patients with solid organ tumours. ( Aldaz, A; Brugarolas, A; Giráldez, J; Ortega, A, 1999) |
| "The Cockcroft-Gault and Salazar-Corcoran equations were compared with respect to prediction of gentamicin pharmacokinetic values in obese and nonobese patients, and the results were used to formulate guidelines for calculating initial gentamicin dosages in obese patients." | 1.29 | Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients. ( Chandler, MH; Leader, WG; Tsubaki, T, 1994) |
| " Bioavailability was 83." | 1.28 | Pharmacokinetics of gentamicin after intravenous and subcutaneous injection in obese cats. ( Clark, CH; Horton, CR; Jernigan, AD; Wilson, RC; Wright, LC, 1991) |
| "We examined gentamicin dosage based on body surface area (60 mg/m2 intravenously every eight hours) as a means of attaining therapeutic but nontoxic serum concentrations in 58 patients ranging in age from 0." | 1.26 | Predictability of peak serum gentamicin concentration with dosage based on body surface area. ( Levin, MJ; Siber, GR; Smith, AL, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (40.91) | 18.7374 |
| 1990's | 4 (18.18) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (31.82) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, AH | 1 |
| Kwok, CHR | 1 |
| Jacques, A | 1 |
| Stopher, L | 1 |
| Hockley, JA | 1 |
| Garbowski, MW | 1 |
| Jansen, SJ | 1 |
| Hodiamont, CJ | 1 |
| van den Broek, AK | 1 |
| de Vroom, SL | 1 |
| Prins, JM | 1 |
| Mathôt, RAA | 1 |
| van Hest, RM | 1 |
| Moffett, BS | 2 |
| Kam, C | 1 |
| Galati, M | 1 |
| Schmees, L | 1 |
| Stitt, GA | 1 |
| Revell, PA | 1 |
| Palazzi, DL | 2 |
| Crass, RL | 1 |
| Ross, BE | 1 |
| Derstine, BA | 1 |
| Lichty, M | 1 |
| Sullivan, JA | 1 |
| Su, GL | 1 |
| Wang, SC | 1 |
| Pai, MP | 3 |
| Gai, Z | 1 |
| Visentin, M | 1 |
| Hiller, C | 1 |
| Krajnc, E | 1 |
| Li, T | 1 |
| Zhen, J | 1 |
| Kullak-Ublick, GA | 1 |
| Thuny, F | 1 |
| Richet, H | 1 |
| Casalta, JP | 1 |
| Angelakis, E | 1 |
| Habib, G | 1 |
| Raoult, D | 1 |
| Choi, JJ | 1 |
| McDade, EJ | 1 |
| Nafziger, AN | 1 |
| Bertino, JS | 1 |
| Chen, WZ | 1 |
| Garba, A | 1 |
| Cui, H | 1 |
| Zaffo, B | 1 |
| El-Fawal, HA | 1 |
| Mousa, SA | 1 |
| Kaminski, DL | 1 |
| Jellinek, M | 1 |
| Mueller, EJ | 1 |
| Korsager, S | 1 |
| Sketris, I | 1 |
| Lesar, T | 1 |
| Zaske, DE | 1 |
| Cipolle, RJ | 1 |
| Leader, WG | 1 |
| Tsubaki, T | 1 |
| Chandler, MH | 1 |
| Ortega, A | 2 |
| Aldaz, A | 2 |
| Giráldez, J | 2 |
| Brugarolas, A | 2 |
| Schwartz, SN | 1 |
| Pazin, GJ | 1 |
| Lyon, JA | 1 |
| Ho, M | 1 |
| Pasculle, AW | 1 |
| Siber, GR | 1 |
| Smith, AL | 1 |
| Levin, MJ | 1 |
| Wright, LC | 1 |
| Horton, CR | 1 |
| Jernigan, AD | 1 |
| Wilson, RC | 1 |
| Clark, CH | 1 |
| Keller, F | 1 |
| Corcoran, GB | 1 |
| Salazar, DE | 1 |
| Gibbs, RS | 1 |
| Blanco, JD | 1 |
| Lipscomb, KA | 1 |
| Rudolph, RI | 1 |
| Gross, PR | 1 |
1 review available for gentamicin and Obesity
| Article | Year |
|---|---|
Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review.
Topics: Adult; Aged; Anti-Bacterial Agents; Body Weight; Child; Critical Illness; Gentamicins; Humans; Infan | 2022 |
21 other studies available for gentamicin and Obesity
| Article | Year |
|---|---|
Gentamicin-Containing Collagen Implant May Reduce Surgical Site Infections After Open Infrainguinal Arterial Revascularization.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Arterial Occlusive Diseases; Diabetes Complications; | 2022 |
The "Ideal" Body Weight for Pediatric Gentamicin Dosing in the Era of Obesity: A Population Pharmacokinetic Analysis.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Cohort Studies; Dose-Response Relationsh | 2018 |
Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance across Body Size.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Body Size; Female; Gentamicins; Humans; Male; Middl | 2018 |
Organic Cation Transporter 2 Overexpression May Confer an Increased Risk of Gentamicin-Induced Nephrotoxicity.
Topics: Animals; Cell Line; Diet, High-Fat; Female; Gentamicins; HEK293 Cells; Humans; Kidney; Kidney Diseas | 2016 |
Vancomycin treatment of infective endocarditis is linked with recently acquired obesity.
Topics: Age Factors; Aged; Anti-Bacterial Agents; Body Mass Index; Drug Therapy, Combination; Endocarditis; | 2010 |
Altered gentamicin serum concentrations in obese pediatric patients.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Cohort Studies; Female; Gentamicins; Hum | 2011 |
Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoglycosides; Body Mass Index; Female; Gentamicins; G | 2011 |
Effects of obesity and sex on antimicrobial pharmacokinetics and acute kidney injury: validation of a preclinical model.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Animals; Anti-Bacterial Agents; Cell Adhesion Molecules; | 2013 |
The effect of antibiotics on hepatic lipid metabolism following small bowel bypass.
Topics: Acetyl-CoA Carboxylase; Animals; Cholesterol; Clindamycin; Fatty Acid Synthases; Gentamicins; Intest | 1980 |
Administration o gentamicin to obese patients.
Topics: Adipose Tissue; Aged; Body Weight; Female; Gentamicins; Humans; Male; Middle Aged; Models, Biologica | 1980 |
Effect of obesity on gentamicin pharmacokinetics.
Topics: Adult; Female; Gentamicins; Humans; Kinetics; Obesity | 1981 |
Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients.
Topics: Adult; Bias; Body Surface Area; Body Weight; Creatinine; Female; Gentamicins; Humans; Male; Metaboli | 1994 |
Population pharmacokinetic parameters of gentamicin in patients with solid tumors: estimation by one- and two-stage methods.
Topics: Adult; Aged; Analysis of Variance; Anti-Bacterial Agents; Cohort Studies; Drug Monitoring; Female; F | 1998 |
Relationship between pharmacokinetic parameters of gentamicin and patient characteristics and/or clinical data in patients with solid organ tumours.
Topics: Creatinine; Dose-Response Relationship, Drug; Female; Gentamicins; Humans; Leukocytes; Middle Aged; | 1999 |
A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects.
Topics: Anti-Bacterial Agents; Body Weight; Gentamicins; Humans; Kinetics; Obesity; Tobramycin | 1978 |
Predictability of peak serum gentamicin concentration with dosage based on body surface area.
Topics: Adolescent; Adult; Aged; Body Surface Area; Cachexia; Child; Child, Preschool; Extracellular Space; | 1979 |
Pharmacokinetics of gentamicin after intravenous and subcutaneous injection in obese cats.
Topics: Animals; Biological Availability; Cat Diseases; Cats; Female; Gentamicins; Injections, Intravenous; | 1991 |
Gentamicin volume of distribution as a power function of body weight.
Topics: Adult; Body Weight; Gentamicins; Humans; Infant; Infant, Newborn; Obesity | 1989 |
Obesity as a risk factor in drug-induced organ injury. IV. Increased gentamicin nephrotoxicity in the obese overfed rat.
Topics: Acetylglucosaminidase; Animals; Gentamicins; Hydrogen-Ion Concentration; Kidney; Male; Obesity; Rats | 1989 |
Aminoglycoside dosing in obese puerperal women.
Topics: Adult; Aminoglycosides; Endometritis; Female; Gentamicins; Humans; Obesity; Postpartum Period; Pregn | 1985 |
Elephantiasis nostras verrucosa of the panniculus.
Topics: Abdominal Muscles; Administration, Topical; Diet Therapy; Female; Gentamicins; Heart Failure; Humans | 1973 |